Citations

Clear

2303 citation(s) found for "Yu, Edward".

Progressive hydrocephalus despite early complete reversal of hindbrain herniation after prenatal open myelomeningocele repair
Lu, Victor M. , Snyder, Kendall, Ibirogba, Eniola R. , Ahn, Edward S. , Ibirogba, Eniola R , Ruano, Rodrigo , Daniels, David J.

Mayo Clinic

Neurosurgical Focus | October 4, 2019 | Volume: 47 | Issue: 4 | Pages: E13

10.3171/2019.7.focus19434 | PMID 31574467 Get It

OBJECTIVE Open prenatal myelomeningocele (MMC) repair is typically associated with reversal of in utero hindbrain herniation (HBH) and has been posited to be associated with a reduction in both postoperative prenatal and immediate postnatal hydrocephalus (HCP) risks. However, the long-term postnatal risk of HCP following HBH reversal in these cases has not been well defined. The authors describe the results of a long-term HCP surveillance in a cohort of patients who underwent prenatal MMC repair at their institution. METHODS A retrospective review of all prenatal MMC repair operations performed at the Mayo Clinic between 2012 and 2017 was conducted. Pertinent data regarding the clinical courses of these patients before and after MMC repair were summarized. Outcomes of interest were occurrences of HBH and HCP and the need for intervention. RESULTS A total of 9 prenatal MMC repair cases were identified. There were 7 cases in which MRI clearly demonstrated prenatal HBH, and of these 86% (6/7) had evidence of HBH reversal after repair and prior to delivery. After a mean postnatal follow-up of 20 months, there were 3 cases of postnatal HCP requiring intervention. One case that failed to show complete HBH reversal after MMC repair required early ventriculoperitoneal shunting. The other 2 cases were of progressive, gradual-onset HCP despite complete prenatal HBH reversal, requiring endoscopic third ventriculostomy with choroid plexus cauterization at ages 5 and 7 months. CONCLUSIONS Although prenatal MMC repair can achieve HBH reversal in a majority of well-selected cases, the prevention of postnatal HCP requiring intervention appears not to be predicated on this outcome alone. In fact, it appears that in a subset of cases in which HBH reversal is achieved, patients can experience a progressive, gradual-onset HCP within the 1st year of life. These findings support continued rigorous postnatal surveillance of all prenatal MMC repair patients, irrespective of postoperative HBH outcome.
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
Fitzmaurice, Christina , Abate, Degu , Abbasi, Naghmeh , Abbastabar, Hedayat , Abdelalim, Ahmed , Abdoli, Amir , Abdulle, Abdishakur S. M., Abebe, Nebiyu Dereje , Abraha, Haftom Niguse , Abualhasan, Ahmed , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Afarideh, Mohsen , Afshari, Mahdi , Aghaali, Mohammad , Agius, Dominic, Agrawal, Sutapa , Ahmadi, Ayat , Ahmed, Muktar Beshir , Akbari, Mohammad Esmaeil , AlAbdulKader, Assim M. , Alahdab, Fares , Alam, Shazia , Alamene, Genet Melak, Alene, Kefyalew Addis , Alipour, Vahid, Bakeshei, Fatemeh Allah, Almadi, Majid A. , Alsharif, Ubai , Alsowaidi, Shirina, Alvis‐Guzmán, Nelson , Amini, Saeed, Anbari, Zohreh , Anber, Nahla , Andrei, Cătălina Liliana , Anjomshoa, Mina, Ansari, Fereshteh, Ansariadi, Ansariadi , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Areri, Habtamu Abera , Artaman, Al, Asfaw, Ephrem Tsegay, Ashagre, Alebachew Fasil, Assadi, Reza , Atalay, Hagos Tasew , Ataro, Zerihun , Atique, Suleman , Ávila‐Burgos, Leticia , Avokpaho, Euripide , Awasthi, Ashish , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayanore, Martin Amogre , Ayele, Henok Tadesse, Babaee, Ebrahim , Bacha, Umar, Badawi, Alaa, Bagherzadeh, Mojtaba , Bagli, Eleni , Balakrishnan, Senthilkumar , Bärnighausen, Till , Battista, Robert J., Behzadifar, Meysam, Belay, Yared Belete , Berfield, Kathleen, Berhane, Adugnaw , Bernabé, Eduardo , Beuran, Mircea , Bhakta, Nickhill , Bhattacharyya, Krittika , Biadgo, Belete , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Bisignano, Catherine, Bitew, Helen , Bjørge, Tone , Bogale, Kassawmar Angaw , Bojia, Hunduma Amensisa, Borzì, Antonio Maria , Bou-Orm, Ibrahim R. , Brenner, Hermann , Brewer, Jerry D., Briko, Andrey , Брико, Н. И. , Bustamante-Teixeira, Maria Teresa , Butt, Zahid A , Carreras, Giulia , Carvalho, Félix , Castro, Clara , Castro, Franz , Catalá-López, Ferrán , Cerin, Ester , Chaiah, Yazan , Chanie, Wagaye Fentahun, Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chauhan, Neelima Singh, Chiang, Peggy Pei-Chia, Chichiabellu, Tesfaye Yitna , Chido‐Amajuoyi, Onyema Greg , Chimed‐Ochir, Odgerel , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Crowe, Christopher S. , Curado, María Paula , Dahlawi, Saad M A , Damiani, Giovanni , Darwish, Amira Hamed , Demissie, Birhanu Wondimeneh , Demoz, Gebre Teklemariam , Derakhshani, Afshin , Deribe, Kalkidan Solomon, Desai, Rupak , Desalegn, Beruk Berhanu , Dey, Subhojit , Dhimal, Meghnath , Díaz, Daniel , Dinberu, Mesfin Tadese, Djalalinia, Shirin, Drake, Thomas M , Dubljanin, Eleonora , Duken, Eyasu Ejeta, Effiong, Andem , Eftekhari, Aziz , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Elemineh, Demelash Abewa , Elkout, Hajer , Ellenbogen, Richard G. , Elsharkawy, Aisha , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Endries, Aman Yesuf , Eshrati, Babak, Fadhil, Ibtihal , Farzadfar, Farshad , Fentahun, Netsanet , Fernandes, Eduarda , Feyissa, Garumma Tolu , Fischer, Florian , Fisher, James L. , Force, Lisa M , Freitas, Marisa , Fukumoto, Takeshi , Futran, Neal D. , Gallus, Silvano , Gankpé, Fortuné Gbètoho , Gayesa, Reta Tsegaye, Gebrehiwot, Tsegaye Tewelde , Gebremeskel, Gebreamlak Gebremedhn , Gedefaw, Getnet , Gelaw, Belayneh K., Geta, Birhanu, Getachew, Sefonias , Gezae, Kebede Embaye , Ghafourifard, Mansour , Ghajar, Alireza , Ghashghaee, Ahmad , Gholamian, Asadollah , Ginindza, Themba G. , Girmay, Alem, Gizaw, Muluken , Gomez, Ricardo Santiago , Gopalani, Sameer Vali , Gorini, Giuseppe , Goulart, Bárbara Niegia Garcia de , Grada, Ayman , Guerra, Maximiliano Ribeiro, Guimarães, André Luiz Sena , Gupta, Prakash C. , Hadkhale, Kishor , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hamidi, Samer , Hanfore, Lolemo Kelbiso , Hasankhani, Milad , Hasanzadeh, Amir , Hassen, Hamid Yimam , Hay, Simon I , Henok, Andualem , Herţeliu, Claudiu , Hoang, Chi Linh , Hole, Michael K., Hoogar, Praveen , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela, Hostiuc, Sorin , Househ, Mowafa , Hussen, Mohammedaman Mama, Ileanu, Bogdan Vasile , Ilić, Milena , Innos, Kaire , Irvani, Seyed Sina Naghibi , Iseh, Kufre Robert , Islam, Sheikh Mohammed Shariful , Balalami, Nader Jafari, Jafarinia, Morteza , Jahangiry, Leila , Jahanmehr, Nader , Jakovljević, Mihajlo, James, Spencer L , Jayaraman, Sudha , Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Jürisson, Mikk , Kamangar, Farin , Karimi, Narges , Karimian, Ansar , Kasaeian, Amir , Kasahun, Gebremicheal Gebreslassie , Kassa, Belete, Kassaw, Mesfin Wudu , Kaul, Anil, Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khalilarjmandi, Maryam, Khan, Ejaz Ahmad , Khan, Gulfaraz , Khang, Young-Ho, Khater, Amir M, Khayamzadeh, Maryam , Khazaee-Pool, Maryam , Khosravi, Mohammad Hossein , Khubchandani, Jagdish , Kianipour, Neda, Kim, Daniel , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Krohn, Kristopher J, Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kuupiel, Desmond , Lad, Deepesh , Lake, Eyasu Alem , Lakew, Ayenew Molla , Lal, Dharmesh Kumar, Lami, Faris , Lan, Qing , Lasrado, Savita , Lazarus, Jeffrey V. , Leigh, James , Leshargie, Cheru Tesema , Liao, Yu , Limenih, Miteku Andualem , Listl, Stefan , Lopukhov, Platon D , Lunevičius, Raimundas , Madadin, Mohammed , Razek, Hassan Magdy Abd El , Majeed, Azeem , Manafi, Ali, Manafi, Navid , Manamo, Wondimu Ayele, Mantovani, LG , Martini, Santi , Mashamba-Thompson, Tivani P. , Massenburg, Benjamin B. , Maswabi, Motswadi Titus, McAlinden, Colm , Meheretu, Hailemariam Abiy Alemu , Mehrotra, Ravi , Meles, Gebrekiros Gebremichael , Meles, Hagazi Gebre , Melku, Mulugeta , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Merat, Shahin , Meretoja, Tuomo J , Miazgowski, Bartosz , Miazgowski, Tomasz , Mihretie, Kebadnew Mulatu M., Miller, Ted R. , Mills, Edward J , Mir, Seyed Mostafa , Mishra, Rashmi , Moazen, Babak , Mohammad, Dara K., Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Moslem, Mohammadian, Mahdi , Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Ammas Siraj , Mohammed, Jemal , Mohammed, Shafiu , Mohebi, Farnam , Mokdad, Ali H. , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moossavi, Maryam , Moradi, Ghobad , Moradi-Joo, Mohammad , Moradpour, Farhad , Morawska, Lídia , Morgado-da-Costa, Joana, Mosapour, Abbas , Mousavi, Seyyed Meysam , Muche, Achenef Asmamaw , Muhammed, Oumer Sada , Musa, Jonah , Nabhan, Ashraf , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Nagel, Gabriele , Naik, Gurudatta , Nam, Hae‐Sung , Nazari, Javad , Negoi, Ionuţ , Neupane, Subas , Nggada, Haruna Asura , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikniaz, Leila , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Nixon, Molly R, Nnaji, Chukwudi A , Shiadeh, Malihe Nourollahpour , Obsa, Mohammed Suleiman , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olagunju, Tinuke O , Oluwasanu, Mojisola , Omonisi, Abidemi , Onwujekwe, Obinna , Oommen, Anu Mary , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakpour, Amir H. , Pană, Adrian , Park, Eun‐Kee , Patel, Shanti, Patil, Snehal T, Pennini, Alyssa, Piccinelli, Cristiano, Pillay, Julian David , Pirestani, Majid , Postma, Maarten J. , Pourmalek, Farshad , Pourshams, Akram , Prakash, Swayam , Rabiee, Navid , Radfar, Amir , Rafiei, Alireza , Rahim, Fakher , Rahimi, Mahdi , Rahman, Muhammad Aziz , Rajati, Fatemeh , Rana, Saleem M., Raoofi, Samira , Rath, Goura Kishor, Rawaf, David Laith , Reiner, Robert C. , Renzaho, André M. N. , Rezapour, Aziz, Ribeiro, Ana Isabel , Ribeiro, Daniela , Roro, Elias Merdassa , Rostami, Ali , Saad, Ragy , Sabbagh, Parisa , Saddik, Basema , Safiri, Saeid , Salahshoor, Mohammad Reza , Salehi, Farkhonde , Salem, Hosni , Salem, Marwa Rashad , Salimzadeh, Hamideh , Salomon, Joshua A. , Samy, Abdallah M , Sanabria, Juan , Santric-Milicevic, Milena M , Sartorius, Benn , Sarveazad, Arash , Sathian, Brijesh , Satpathy, Maheswar , Savic, Miloje , Sawhney, Monika, Seyedmousavi, Seyedmojtaba , Shaahmadi, Faramarz , Shabaninejad, Hosein , Shahbaz, Mohammad , Shaikh, Masood Ali, Shamshirian, Amir , Shamsizadeh, Morteza , Sharafi, Zeinab , Sharifi, Ali , Sharifi, Hamid , Shirkoohi, Reza , Shukla, Sharvari , Si, Si , Siabani, Soraya , Silva, Diego Augusto Santos , Singh, Ambrish , Sisay, Solomon , Sobngwi, Eugène , Soofi, Moslem , Soriano, Joan B. , Stathopoulou, Vasiliki, Sufiyan, Mu’awiyyah Babale , Tabarés‐Seisdedos, Rafael , Tabuchi, Takahiro , Takahashi, Ken , Tarawneh, Mohammed Rasoul , Tassew, Segen Gebremeskel , Taymoori, Parvaneh , Temsah, Mohamad‐Hani , Temsah, Omar, Tesfay, Fisaha Haile , Teshale, Manaye Yihune, Tessema, Gizachew Assefa , Thapa, Subash , Tlaye, Kenean Getaneh , Topór-Mądry, Roman , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Khanh Bao , Tsadik, Afewerki Gebremeskel , Ullah, Irfan , Vaezi, Maryam, Pérez, Patricia Varona , Vidale, Simone , Violante, Francesco Saverio , Vollset, Stein Emil, Vos, Theo , Vosoughi, Kia , Vu, Giang Thu , Vujcic, Isidora S , Wabinga, Henry, Wachamo, Tesfahun Mulatu , Wagnew, Fasil Shiferaw, Waheed, Yasir , Weldegebreal, Fitsum , Weldesamuel, Girmay Teklay, Wijeratne, Tissa , Wonde, Tewodros Eshete , Workie, Hailemariam Mekonnen , Yadav, Rajaram , Yadegar, Abbas , Yadollahpour, Ali , Yaseri, Mehdi , Yazdi‐Feyzabadi, Vahid , Yeshaneh, Alex , Yimam, Mohammed , Yisma, Engida , Younis, Mustafa Z , Zadnik, Vesna, Moghadam, Telma Zahirian , Zandian, Hamed , Zangeneh, Alireza , Zaki, Leila , Zendehdel, Kazem , Zenebe, Zerihun Menlkalew, Zewale, Taye Abuhay , Ziapour, Arash , Zodpey, Sanjay , Murray, Christopher J L , Topór‐Mądry, Roman , Deribe, Kebede , Teklay, Girmay , Wijeratne, T , Kumar, Vivek , Lazarus, Jeffrey V , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Abd-Allah, Foad , Abdel-Rahman, Omar Mohammed , Abdollahpour, Ibrahim , Abu-Raddad, Laith Jamal , Ahmadian, Elham , Ahmadpour, Ehsan , Akinyemiju, Tomi , Al‐Aly, Ziyad , Alemnew, Birhan , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Erfan , Amini, Saeed, Amoako, Yaw Ampem , Arab-Zozani, Morteza , Asayesh, Hamid , Fasil, Alebachew , Ataeinia, Bahar , Ausloos, Marcel , Balouchi, Abbas , Behzadifar, Masoud , Behzadifar, Meysam, Bekele, Bayu Begashaw , Belayneh, Yaschilal Muche , Birungi, Charles , Bleyer, Archie , Bosetti, Cristina , Carrero, Juan Jesús , Chaturvedi, Pankaj , Chehrazi, Mohammad , Constantin, María Magdalena , Crocetti, Emanuele , Daryani, Ahmad , Neves, José das , Demeke, Feleke Mekonnen , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Deribe, Kalkidan Solomon, Desta, Melaku , Dharmaratne, Samath Dhamminda , Doku, David Teye , Dubey, Manisha , Ebrahimi, Hedyeh , Sayed, Iman El , Zaki, Maysaa El Sayed , Adane, Daniel, Omrani, Vahid Fallah , Faramarzi, Mahbobeh , Farhangi, Mahdieh Abbasalizad , Farioli, Andrea , Filip, Irina , Foroutan, Masoud , Tsegaye, Reta , Gelaw, Belayneh K., Gill, Paramjit Singh , Gupta, Rahul, Haro, Josep María , Hay, Roderick J. , Henry, Nathaniel J , Hidru, Hagos Degefa , Horita, Nobuyuki , Hosgood, H. Dean, Hostiuc, Mihaela, Hussen, Mohammedaman Mama, Islami, Farhad , Jahani, Mohammad Ali , Jakovljević, Mihajlo , Javanbakht, Mehdi , Jee, Sun Ha , Jenabi, Ensiyeh , Jonnagaddala, Jitendra, Jungari, Suresh Banayya , Kabir, Ali , Karch, André , Kassa, Tesfaye , Kerbo, Amene Abebe , Khang, Young-Ho, Khatab, Khaled , Khazaei, Salman , Khoja, Abdullah T , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Vecchia, Carlo La , Lal, Dharmesh Kumar, Lauriola, Paolo , Lopez, Alan D , Magdeldin, Sameh , Maleki, Afshin , Malekzadeh, Reza , Manamo, Wondimu Ayele, Mansourian, Morteza , Mansournia, Mohammad Alì , Maroufizadeh, Saman , Mathur, Manu Raj , McKee, Martin , Mehta, Varshil , Meier, Toni , Melaku, Yohannes Adama , Melese, Addisu Dagnaw , Meštrović, Tomislav , Mulatu, Kebadnew , Mirzaei, Hamed , Mirzaei, Hamid Reza , Mohammad, Dara K., Darwesh, Aso Mohammad , Mohammadbeigi, Abolfazl , Mohammadi, Hiwa , Mohammadi, Moslem, Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Nahvijou, Azin , Najafi, Farid , Naldi, Luigi , Nasiri, Naser , Newcomb, Polly A. , Nojomi, Marzieh , Nosratnejad, Shirin , Oh, In‐Hwan , Oren, Eyal , Ota, Erika , Owolabi, Mayowa , Parsian, Hadi , Pashaei, Tahereh , Pereira, David M. , Pishgar, Farhad , Pourjafar, Hadi , Prasad, Narayan , Qorbani, Mostafa , Rabiee, Mohammad , Rana, Saleem M., Rawaf, Salman , Rezaei, Nima , Ronfani, Luca , Roshandel, Gholamreza , Saad, Ragy , Sabbagh, Parisa, Sabour, Siamak , Sahebkar, Amirhossein , Sayyah, Mehdi , Schneider, Ione Jayce Ceola , Schöttker, Ben , Šekerija, Mario , Sepanlou, Sadaf Ghajarieh , Sepehrimanesh, Masood , Sharafi, Heidar , Sharif, Mehdi , Sharma, Rajesh , Sheikh, Aziz , Silveira, Dayane Gabriele Alves , Singh, Jasvinder A. , Sitas, Freddy , Tamtaji, Omid Reza , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Teshale, Manaye Yihune, Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Vacante, Marco , Vaezi, Maryam, Veisani, Yousef , Vlassov, Vasily , Vollset, Stein Emil, Wagnew, Fasil , Wondafrash, Dawit Zewdu , Wondmieneh, Adam Belay , Yimer, Ebrahim M , Yonemoto, Naohiro , Yousefi, Bahman , Yousefifard, Mahmoud , Yu, Chuanhua , Zabeh, Erfan , Zaidi, Zoubida , Zamani, Mohammad , Olagunju, Andrew T , Bhakta, Nickhill , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

JAMA Oncology | September 27, 2019 | Volume: 5 | Issue: 12 | Pages: 1749

10.1001/jamaoncol.2019.2996 | PMID 31560378 Get It

Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn’s Disease: Are There Differences in the Safety Profiles?
McKenna, Nicholas P. , Alsughayer, Ahmad, Harmsen, William S. , Taparra, Kekoa , Parker, Maile E., Raffals, Laura E. , Loftus, Edward V. , Loftus, Edward V , McKenna, Nicholas P , Lightner, Amy L.

Mayo Clinic

Diseases of the Colon & Rectum | September 24, 2019 | Volume: 62 | Issue: 11 | Pages: 1352-1362

10.1097/dcr.0000000000001482 | PMID 31567927 Get It

BACKGROUND: The evidence regarding the association of preoperative biologic exposure and postoperative outcomes remains controversial for both antitumor necrosis factor agents and vedolizumab and largely unknown for ustekinumab. OBJECTIVE: The purpose of this study was to determine differences in the rates of 30-day postoperative overall infectious complications and intra-abdominal septic complications among the 3 classes of biologic therapies as compared with no biologic therapy. DESIGN: This was a retrospective review. SETTINGS: The study was conducted at an IBD referral center. PATIENTS: Adult patients with Crohn’s disease who received an antitumor necrosis factor, vedolizumab, ustekinumab, or no biologic therapy within 12 weeks of a major abdominal operation between May 20, 2014, and December 31, 2017, were included. MAIN OUTCOMES MEASURES: Thirty-day overall postoperative infectious complications and intra-abdominal septic complications were measured. RESULTS: A total of 712 patients with Crohn’s disease were included; 272 patients were exposed to an antitumor necrosis factor agents, 127 to vedolizumab, 38 to ustekinumab, and 275 to no biologic therapy within the 12 weeks before an abdominal operation. Patients exposed to a biologic were more likely to be taking a concurrent immunomodulator, but there was no difference in concurrent corticosteroid usage. The particular class of biologic was not independently associated with total overall infectious complications. Vedolizumab was associated with an increased rate of intra-abdominal sepsis on univariate analysis but not on multivariable analysis. Combination immunosuppression was associated with both an increased rate of overall postoperative infectious complications and intra-abdominal sepsis. LIMITATIONS: The study was limited by its retrospective design and single-center data. CONCLUSIONS: The overall rate of total infectious complications or intra-abdominal septic complications was not increased based on preoperative exposure to a particular class of biologic. Rates increased with combination immunosuppression of biologic therapy with corticosteroids and previous abdominal resection. See Video Abstract at http://links.lww.com/DCR/B24. BIOLÓGICOS Y COMPLICACIONES POSTOPERATORIAS DE 30 DÍAS DESPUÉS DE LAS OPERACIONES ABDOMINALES PARA LA ENFERMEDAD DE CROHN: ¿EXISTEN DIFERENCIAS EN LOS PERFILES DE SEGURIDAD?: ANTECEDENTES: La evidencia sobre la asociación de la exposición biológica preoperatoria y los resultados postoperatorios sigue siendo controvertida controversial tanto para los agentes del factor de necrosis tumoral (anti-TNF) como para el vedolizumab, y en gran parte desconocida para el ustekinumab. OBJETIVO: Determinar las diferencias en las tasas de complicaciones infecciosas generales postoperatorias de 30 días y complicaciones sépticas intraabdominales entre las tres clases de terapias biológicas en comparación con ninguna terapia biológica. DISEÑO: Revisión retrospectiva. AMBIENTE: centro de referencia de la enfermedad inflamatoria intestinal. PACIENTES: Pacientes adultos con enfermedad de Crohn que recibieron un factor de necrosis antitumoral, vedolizumab, ustekinumab o ningún tratamiento biológico dentro de las 12 semanas de una operación abdominal mayor entre el 5/20/2014 y el 12/31/2017. PRINCIPALES MEDIDAS DE RESULTADOS: Complicaciones infecciosas postoperatorias generales de 30 días, complicaciones sépticas intraabdominales. RESULTADOS: Se incluyeron setecientos doce pacientes con enfermedad de Crohn; 272 pacientes fueron expuestos a un anti-TNF, 127 a vedolizumab, 38 a ustekinumab y 275 a ninguna terapia biológica dentro de las 12 semanas previas a una operación abdominal. Los pacientes expuestos a un producto biológico tenían más probabilidades de tomar un inmunomodulador concurrente, pero no hubo diferencias en el uso simultáneo de corticosteroides. La clase particular de productos biológicos no se asoció de forma independiente con las complicaciones infecciosas totales. Vedolizumab se asoció con una mayor tasa de sepsis intraabdominal en el análisis univariable, pero no en el análisis multivariable. La inmunosupresión combinada se asoció tanto con una mayor tasa de complicaciones infecciosas postoperatorias generales como con sepsis intraabdominal. LIMITACIONES: Diseño retrospectivo, datos de centro único. CONCLUSIONES: La tasa general de complicaciones infecciosas totales o complicaciones sépticas intraabdominales no aumentó en función de la exposición preoperatoria a una clase particular de productos biológicos. Las tasas aumentaron con la combinación de inmunosupresión de la terapia biológica con corticosteroides y resección abdominal previa. Vea el Resumen del Video en http://links.lww.com/DCR/B24.
Economic impact of contact force sensing in catheter ablation for atrial fibrillation
Mansour, Moussa , Reddy, Vivek Y. , Karst, Edward , Heist, E. Kevin , Packer, Douglas L. , Dalal, Nirav, Agarwal, Rahul , Calkins, Hugh , Ruskin, Jeremy N. , Mahapatra, Srijoy, Heist, Edwin Kevin , Reddy, Vivek Y

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 24, 2019 | Volume: 30 | Issue: 11 | Pages: 2302-2309

10.1111/jce.14189 | PMID 31549456 Get It

AbstractAimsThe TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) clinical trial compared clinical outcomes using a contact force (CF) sensing ablation catheter (TactiCath) with a catheter that lacked CF measurement. This analysis links recorded events in the TOCCASTAR study and a large claims database, IBM MarketScan®, to determine the economic impact of using CF sensing during atrial fibrillation (AF) ablation.Methods and ResultsClinical events including repeat ablation, use of antiarrhythmic drugs, hospitalization, perforation, pericarditis, pneumothorax, pulmonary edema, pulmonary vein stenosis, tamponade, and vascular access complications were adjudicated in the year after ablation. CF was characterized as optimal if greater than or equal to 90% lesion was performed with greater than or equal to 10 g of CF. A probabilistic 1:1 linkage was created for subjects in MarketScan® with the same events in the year after ablation, and the cost was evaluated over 10 000 iterations. Of the 279 subjects in TOCCASTAR, 145 were ablated using CF (57% with optimal CF), and 134 were ablated without CF. In the MarketScan® cohort, 9811 subjects who underwent AF ablation were used to determine events and costs. For subjects ablated with optimal CF, total cost was $19 271 ± 3705 in the year after ablation. For ablation lacking CF measurement, cost was $22 673 ± 3079 (difference of $3402, P < .001). In 73% of simulations, optimal CF was associated with lower cost in the year after ablation.ConclusionCompared to ablation without CF, there was a decrease in healthcare cost of $3402 per subject in the first year after the procedure when optimal CF was used.
Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine
Jung, Deok‐Beom , Yun, Miyong , Kim, Eun-Ok , Kim, Bonglee , Wang, Enfeng , Hammond, Edward , Dredge, Keith , Shridhar, Viji , Kim, Jaekwang , Jung, Ji Hoon , Mukhopadhyay, Debabrata , Hammond, Edward, Kim, Sung‐Hoon

Mayo Clinic

Oncotarget | September 24, 2019 | Volume: 10 | Issue: 54 | Pages: 5669-5669

10.18632/oncotarget.27216 | PMID 31608142 Get It

American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies
Tuan, Rocky S. , Awad, Hani A. , Bunnell, Bruce A. , Colnot, Céline , Drissi, Hicham , Dyment, Nathaniel A. , Fortier, Lisa A. , Guldberg, Robert E. , Little, David G. , Marshall, Mary Faith , Mao, Jeremy J. , Proffen, Benedikt L. , Rosen, Vicki , Thomopoulos, Stavros , Serra, Rosa , Tuan, Rocky S , Awad, Hani A , Drake, Matthew T. , Kandel, Rita A. , Proffen, Benedikt L , Rodeo, Scott A , Schwarz, Edward M , Serra, Rosa , Dyment, Nathaniel A , O’Keefe, Regis J. , Lane, Nancy E. , Barry, Frank , Nakamura, Norimasa , Rodeo, Scott A. , Schwarz, Edward M.

Mayo Clinic

Journal of Bone and Mineral Research | September 23, 2019 | Volume: 35 | Issue: 1 | Pages: 3-17

10.1002/jbmr.3839 | PMID 31545883 Get It

ABSTRACT Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2019 American Society for Bone and Mineral Research.
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, Robert B., Adib, Gemma, Adler, Robert A. , Alexander, Ivy M. , Amenta, Kelly C, Blank, Robert D. , Brox, W. Timothy , Carmody, Emily E., Chapman‐Novakofski, Karen , Cody, Kathleen, Cooper, Cyrus , Crandall, Carolyn , Dirschl, Douglas R. , Eagen, Thomas J. , Elderkin, Ann L, Fujita, Masaki , Greenspan, Susan L., Halbout, Philippe , Hochberg, Marc C. , Jeray, Kyle J. , Kearns, Ann E. , King, Toby, Koinis, Thomas F., Koontz, Jennifer Scott , Kužma, Martin , Lindsey, Carleen, Lorentzon, Mattias , Lyritis, George P., Michaud, Laura Boehnke, Miciano, Armando S., Mujahid, Nadia , Olenginski, Thomas P. , Puzas, J. Edward, Rizou, Stavroula , Thompson, Elizabeth , Tosi, Laura L. , Tracer, Howard, Clarke, Bart L , Cooper, Cyrus , Crandall, Carolyn J , Kužma, Martin , Morin, Suzanne N , Napoli, Nicola , Khosla, Sundeep , Lorentzon, Mattias , Åkesson, Kristina , Clarke, B.L. , Javaid, M K , Rosen, Clifford J. , Saag, Kenneth G. , Khosla, Sundeep , Kiel, Douglas P.

Mayo Clinic

Journal of Bone and Mineral Research | September 20, 2019 | Volume: 35 | Issue: 1 | Pages: 36-52

10.1002/jbmr.3877 | PMID 31538675 Get It

ABSTRACT Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fracture among people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, and subcutaneous pharmacotherapies are efficacious and can reduce risk of future fracture. Patients need education, however, about the benefits and risks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first-line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive but may be beneficial for selected patients at high risk. Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the early post-fracture period, prompt treatment is recommended. Adequate dietary or supplemental vitamin D and calcium intake should be assured. Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects. Patients should be strongly encouraged to avoid tobacco, consume alcohol in moderation at most, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease). © 2019 American Society for Bone and Mineral Research.
A Multidisciplinary Team-Based Approach to Improve Communication With Surrogates of Patients With Chronic Critical Illness
Greenberg, Jared A. , Gerhart, James , Horst, Jacqueline N., Chen, Elaine , Hunter, Rebecca L. , O’Mahony, Sean , Yeow, Mei-Ean , Fosler, Laura, LaGorio, Lisa A., Meksraityte, Edita, Weiss, Tyler, Geddes, J., Lambe, Stacy S., Fenton, Kara, Hunter, Rebecca L., Nowak, Kristen, Shah, Raj C.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | September 17, 2019 | Volume: 37 | Issue: 3 | Pages: 214-221

10.1177/1049909119876606 | PMID 31526015 Get It

Background: Clinicians need to deliver prognostic information to surrogates of nondecisional, critically ill patients so that surrogates can make informed medical decisions that reflect the patient’s values. Our objective was to implement a new approach for communicating with surrogates of patients with chronic critical illness. Methods: Surrogate decision makers of patients who were difficult to liberate from mechanical ventilation were prospectively enrolled. Surrogates met with different members of the intensive care unit treatment team for sequential 15-minute appointments to receive patient-specific assessments and education on chronic critical illness. The feasibility and acceptability of this approach were determined. A 24-question comprehension instrument was developed to assess a participant’s understanding that a family member was displaying features of chronic critical illness. Each question was scored from 1 to 5, with larger scores indicating greater comprehension. Results: Over a 15-week period, educational sessions for 9 mechanically ventilated patients were conducted. On average, 2 surrogates per patient (range: 1-4) and 6 members of the interdisciplinary team (range: 4-6) were at each meeting. Surrogates and clinicians had very positive impressions of the communication intervention. The average preintervention comprehension score was 85 of 120 (standard deviation [SD]: 8, range: 71-101). The postintervention comprehension score was greater by 5 points on average (SD: 9, range: −11 to +20 points, P = .04). Conclusions: Surrogates of critically ill patients approved of this novel communication approach and had a greater understanding of the patient’s medical condition after the intervention.